THURSDAY, SEPTEMBER 29, 2016

Genocea Biosciences announces new appointment

Genocea Biosciences, Inc., a Cambridge, Massachusetts-based, clinical-stage vaccine developer, announced a new appointment on Monday to the position of chairman of the board.

Katrine Bosley, who previously served as an independent board member, will now serve as chairman of the board of directors. George Siber, the previous chairman will continue in his positions of executive director of the board of directors and the head of the company's scientific advisory board.

"We are fortunate to continue to draw on Katrine and George's expertise," Chip Clark, the CEO of Genocea, said. "George, a leading authority on vaccines, will continue to play a central role in our portfolio development. Katrine's business experience will help guide our continued growth as a company. Together, the new roles for Katrine and George support our ambition to continue to advance pioneering new vaccines."

Bosley is currently the entrepreneur-in-residence at The Broad Institute and previously held positions as the CEO at Avila Therapeutics and the vice president of business development at Adnexus Therapeutics. Siber was most recently the executive vice president and chief scientific officer of Wyeth Vaccines.

Genocea's lead programs include GEN-004, a vaccine candidate to prevent Pneumococcus infections, and GEN-003, a therapeutic vaccine candidate to treat people infected with herpes simplex type II. Genocea uses the power of T cell immunity to develop new vaccine candidates.